## RECEIVED CENTRAL FAX CENTER 2001

MAR 3 0 2005



Attorneys at Law

March 30, 2005

Suite 2800 1100 Peachtree St. Atlanta GA 30309-4530 t 404 815 6500 f 404 815 6555 www.KilpatrickStockton.com

direct dial 404 745 2470 direct fax 404 541 3297 JMcDonald@KilpatrickStockton.com

## **FAX**

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE, COU	
Centralized Facsimile No. GAU 3621	703.872.9306	U.S. Patent and Tradem Alexandria, VA 22313	
- 4 T 1 C D 11 D) D			
John K. McDonald, Ph.D.		PAGES (WITH COVER)	
0000		55979/313719	
0889 REFERENCE NO		ÇLIENT/MATTER NO.	
PLEASE CALL 404 81:	5 6497 IF YOU HAVE DIFF	ICULTY WITH THIS TRANSMIS	SSION.
<u> </u>			
CONFIDENTIALITY NOTE: The Information contained in this individual named above. If the rethat any dissemination, distributed	ader of this message is not t on or coov of this fax is stric	he intended recipient, you are nere ily prohibited. If you have received	ADA GGAIZAO
The Information contained in this	ader of this message is not t on or coov of this fax is stric	he intended recipient, you are nere ily prohibited. If you have received	ADA GGAIZAO
The Information contained in this individual named above. If the rethat any dissemination, distribute error, please immediately notify u	ader of this message is not to on or copy of this fax is strict is by telephone and destroy to the control of t	ne intended recipient, you are noted by prohibited. If you have received his fax message.	ADÀ GGAIZAG
The Information contained in this individual named above. If the rethat any dissemination, distributed error, please immediately notify u	ader of this message is not to on or copy of this fax is strict by telephone and destroy to the control of the	re intended recipient, you are noted by prohibited. If you have received his fax message.  Production of a Drug for the	ADÀ GGAIZAG
The Information contained in this individual named above. If the rethat any dissemination, distribute error, please immediately notify u  COMMENTS  Applicant:  Title:	Legarda et al.  Use of Flumazenil in the Treatment of Alcohol D.	Production of a Drug for the	ADA GGAIZAO
The Information contained in this individual named above. If the rethat any dissemination, distribution, please immediately notify under the comments of the c	Legarda et al.  Use of Flumazenil in the Treatment of Alcohol D.  10/621,229	re intended recipient, you are noted by prohibited. If you have received his fax message.  Production of a Drug for the	ADÀ GGAIZAG
The Information contained in this individual named above. If the rethat any dissemination, distribute error, please immediately notify u  COMMENTS  Applicant: Title:  Serial No./Docket No.: Filing Date	Legarda et al.  Use of Flumazenil in the Treatment of Alcohol D.	Production of a Drug for the	ADÀ GGAIZAG
The Information contained in this individual named above. If the rethat any dissemination, distribution, please immediately notify use comments  Applicant: Title:  Serial No./Docket No.: Filing Date  PAPERS SUBMITTED: 1. PTO/SB/21 Transm 2. PTO/SB/81 Power of	Legarda et al. Use of Flumazenil in the Treatment of Alcohol D.  10/621,229  7/15/2003	Production of a Drug for the apendency 55979-0100	ADÀ GGAIZAG
The Information contained in this individual named above. If the rethat any dissemination, distributile error, please immediately notify use commediately notificately notific	Legarda et al. Use of Flumazenil in the Treatment of Alcohol D.  10/621,229  7/15/2003  ittal Form of Attorney Correspondence of ent Under 37 CFR 3.73(b)	Production of a Drug for the apendency 55979-0100	ADÀ GGAIZAG
The Information contained in this individual named above. If the rethat any dissemination, distributive error, please immediately notify use commediately notificately no	Legarda et al.  Use of Flumazenil in the Treatment of Alcohol De 10/621,229  7/15/2003  littal Form of Attomey Correspondence of ent Under 37 CFR 3.73(b)	Production of a Drug for the apendency 55979-0100  Address Indication	ADÀ GGAIZAG
The Information contained in this individual named above. If the rethat any dissemination, distributive error, please immediately notify use commediately notificately no	Legarda et al. Use of Flumazenil in the Treatment of Alcohol Do 10/621,229 7/15/2003  Littal Form of Attorney Correspondence of ent Under 37 CFR 3.73(b)  COMPLETED BY KS OPE	Production of a Drug for the apendency 55979-0100  Address Indication	ADA GGAIZAO
The Information contained in this individual named above. If the rethat any dissemination, distributive error, please immediately notify use commediately notificately no	Legarda et al. Use of Flumazenil in the Treatment of Alcohol Do 10/621,229 7/15/2003  Littal Form of Attorney Correspondence of ent Under 37 CFR 3.73(b)  COMPLETED BY KS OPE	Production of a Drug for the apendency 55979-0100  Address Indication	d this fax in

PTO/SB/21 (09-04)

Approved for use through 07/31/2008, OMB 0851-0031

U.S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			Application Number		10/621,2	20	
TRANSMITTAL			<del></del>	<del></del>			
FOR	M		Filing Date		7/15/2003		
			First Named Inven	tor	Legarda	et al.	
			Art Unit		1614	,	
(to be used for all correspond	donce after i	initial filing)	Examiner Name			<del></del>	
Total Number of Pages in This	s Submissi	ion 3	Attorney Docket No	umber	55979-01	00	
		ENCLO	SURES (check all tha	t apply)	<del>'</del>		
Fee Transmittal Form		☐ Drawing(s			After Al	owance Communication to TC	
Fee Attached		Licensing-	related Papers			Communication to Board	
Amendment / Reply		Petition			Appeal	Communication to TC	
After Final Petition to			Convert to a al Application		(Appeal Notice, Brief, Reply Brief)  Proprietary Information		
Affidavits/declaration	(5)	Power of A	Attorney, Revocation f Correspondence Addi	ress	Status L	etter	
Extension of Time Reque	est	Terminal [	Disclaimer			inclosurė(s) dentify below):	
Express Abandonment Request			or Refund er of CD(s)	ļ	-PTO/SB/9 3.73(b)	6 Statement Under 37 CFR	
			dscape Table on CD				
Certified Copy of Priority Document(s)					:	· <del>_</del>	
Reply to Missing Parts/ Incomplete Application							
Reply to Missing Parts							
under 37 CFR1.52 or	r 1.53						
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Firm		Kilpatrick	Stockton, LLP				
Signature			Mond	L			
Printed Name John K. Me			lcDonald, Ph.D.		•••		
Date March			30,2005	Reg. No.	42,860		
			E OF TRANSMISSI		JNG		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.							
Signature	مريحين		· ·	<del></del>			
Typed or printed name Steve Kennedy					Date	Marca 30, 2005	

This collection of information is required by 37 CFR 1.5. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. This will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450. Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

MAR 3 0 2005

Ø 003

de doma B	,	4 1 4 4 4		U.S. Pa	tont and Tracks	mark Office: U.S.	PTC/SB/81 (11-04) bugh 11/30/2005. OMB 0651-0035 DEPARTMENT OF COMMERCE
Under the Paperw	OFK FEBRUE	tion Act of 1995, no persons are req	utrad to nego	that to a colle	ction of Inform	tion unless it dis	plays a valid OMB control remiter.
<b>1</b>		· ·				<u>10/621,229</u>	
POWE	ER OF	ATTORNEY	Filing D			luly 15, 2005	· · · · · · · · · · · · · · · · · · ·
1	a	nd		med inven	t <del>or</del>	Juan Jose i	banez Legarda
CORRESP	OND	ENCE ADDRESS	Title			- of Plantage & In the Pro-	Author of a Casy to try 7 material of Applied Company of
		ON FORM	Art Unit		1	1614	
	IVAII	ON FORM	Examiner Name		bergisea tol	*	
			Attorne	/ Docket N		55979/	
	li previ	ous powers of attorney given	ven in the	above-id	lentified ap	plication.	
I hereby appoint:							
Practitioners as	sociated	with the Customer Number:		23	370		
Practitionar(s) n	vanned be				<u>.                                    </u>		
		Name			Regi	stration Numb	At .
		_	<del></del>				
		· · · · · · · · · · · · · · · · · · ·					
l	<del></del>						
<u> </u>							
					•		
as my/our attomey(s) o Trademark Office cont	or agent( nected th	<ul> <li>s) to prosecute the application is erawith.</li> </ul>	dentified ab	ove, and to	transact eff b	usinese in the	United States Peters and
Closes especiales es et	Mu			-18			
	vange un	e correspondence address for th	e above-ide	antified appl	lication to:		
The address	associat	ed with the above-mentioned Cu	istomer Nu	nber:			
QR .		Г				$\overline{}$	
		•	•	233	アハ	1	
	8880Cf8	led with Customer Number:		<b>200</b>	/ U		i i
OR Firm or			-				
Individual I	Nama						
Address	140110			<del></del>		••	
			<del></del>		<del>,</del>		
City				State	1		Zip
Country							
Telephone				Fax			
lam the:		<del></del>					
Applicant/Inve	entor.						
×							ŀ
		ine entire interest. See 37 CFR ( FR 3.73(b) is enclosed. (Form P					1
		SIGNATURE of A		Assignee	of Record		
Signature	76	uch Jen in		•		Date	9/2.//
	Chuck	Timoe				Telephone	(310) 444-4300
		ancial Officer, Hythiam, Inc.				Lagiothytolia	((310) 444-4300
NOTE: Signatures of all th	e inventur	or assignees of record of the entire	indexingual cor (fr	elr represent	ntive(s) eve neg	uked. Şubmil mı	lible forms if more than one
*Total of 3	DEFOW.		-				
		onns are submitted.	The LO	Name to as a second	and do about		
to complete, including get comments on the amount U.S. Peters and Tradema	nading, pro of time yo rik Office.	ared by 37 CFR 1.31, 1.32 and 1.33, on. Contidentially is governed by 3 operating, and submitting the complete or require to complete this form and U.S. Department of Commerce, P. or To: Commissioner for Paper.	35 U.S.C. 12 M application Vor suggestio O. Box 1450	2 and 37 CFI form to the I ma for reducit	R 1.11 and 1.1 USPTO, Time ng this burden, VA 22313-1/	4. This collection will vary depend should be sent ( 150. DOI MOT (	in its estimated to below 3 minutes ing upon the individual case. Any in the Chief information Officer

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SE/96 (06-04)

Approved for use through (07/31/2006, OMB 0631-033)

U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB centrol number.

STATE	MENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner; Hythlam, Inc.	
Application No./Patent No.: 10/621,229	Filed/Issue Date: July 15, 2003
Entitled: Use of Flumazenii in the Production of a Dr	rug for the Treatment of Alcohol Dependency
Hythiam, Inc. (Name of Assignee)	, a Corporation  (Type of Assignos, e.g., corporation, partnership, university, government evency, etc.)
states that it is:  1.   I the assignee of the entire right, title, and interest in the continuous	
2.   an assignee of less than the entire right, title The extent (by percentage) of its ownership i In the patent application/patent identified above by	end Interest. interest is
A. [ ] An assignment from the inventor(s) of the pa in the United States Patent and Trademark O attached.	atent application/patent identified above. The assignment was recorded office at Reel, Frame, or for which a copy thereof is
OR	
B. [ ] A chain of title from the inventor(s), of the pat below:	tent application/patent identified above, to the current assignee as shown
The document was recorded in the Un	nited States Patent and Trademerk Office at or for which a copy thereof is attached.
2. From:	To:
The document was recorded in the Un	nited States Patent and Trademark Office at, or for which a copy thereof is attached.
3. From:	To:
The document was recorded in the Un	nited States Patent and Trademark Office at , or for which a copy thereof is attached.
[ ] Additional documents in the chain of ti	
[ ] Copies of assignments or other documents in the [NOTE: A separate copy (i.e., a true copy of the submitted to Assignment Division in accordance recorded in the records of the USPTO. See MP	e original assignment document(s)) must be se with 37 CFR Part 3. If the assignment is to be
The undersigned (whose title is supplied below) is a	authorized to act on behalf of the assignee.
3/30/05	Chuck Timpe
Date (310) 444-4300	Typed or printed name
(310) 444-4300 Telephone number	Signature
	Chief Financial Officer
	Cruer Financial Criticar Title

This collection of information is required by ST CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete including pathering, preparing, and submitting the completed application from to the USPTO. Three will very depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestion for reducing this burden, should be easily to the full information Officer, U.S. Potential of Commerce, P.O. 80x 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patients, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.